Abstract
Up to now, the prognostic significance of latent membrane protein 1 (LMP1) in nasopharyngeal carcinoma (NPC) tissues still remains controversial. This study aims to investigate aberrant localization of LMP1 and its relationship with epithelial-mesenchymal transition (EMT) in NPC samples by immunohistochemistry and immunofluorescence. Both cytoplasmic and nuclear LMP1 expressions were observed in NPC tissues. In some tissues, nuclear LMP1 was frequently observed at tumor invasive front and tumor buddings. Nuclear LMP1 expression was significantly associated with lymph node metastasis (P=0.031), local recurrence (P=0.002), lymphatic invasion (P= 0.004) and tumor budding (P=0.001). Furthermore, nuclear LMP1 showed significant correlations with EMT markers including E-cadherin (P=0.037), Vimentin (P < 0.001), N-cadherin (P=0.003), Snail (P=0.003) and Twist (P=0.002), but not significantly linked with Fibronectin (P=0.103) and Slug (P=0.503). According to cytoplasmic LMP1, it correlated strongly with lymphatic invasion (P=0.044), vascular invasion (P=0.003) and EMT proteins including E-cadherin (P=0.014), Vimentin (P=0.006), N-cadherin (P=0.003), Snail (P=0.008) and Slug (P=0.007), whereas not significantly associated with Fibronectin (P=0.221) and Twist (P=0.106). However, multivariate analysis showed that nuclear LMP1 (P=0.844) and cytoplasmic LMP1 (P=0.291) were not independent predictors for NPC. In conclusion, we demonstrate firstly that abnormal localization of LMP1 correlates with EMT properties and aggressiveness in NPC, respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (Grant No. 81202125, 81872202); Natural Science Foundation of Guangdong Province of China (Grant No. 2018A030313778), Natural Science Foundation of Shenzhen (Grant No. JCYJ20190809154603583, JCYJ20210324131210030, JCYJ20200109115420720).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol was approved by the Ethics Committee of Guangdong Medical College
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- LMP1
- Latent membrane protein-1
- NPC
- nasopharyngeal carcinoma
- EMT
- epithelial-mesenchymal transition
- TMA
- tissue microarray
- IHC
- immunohistochemistry
- FFPE
- immunofluorescence labelling of formalin-fixed
- DNKC
- differentiated nonkeratinizing carcinoma
- UDC
- undifferentiatied carcinoma
- T
- tumor size
- HR
- hazard ratio
- CI
- confidence interval
